Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Clearance Index as Endpoint in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa Treated with TOBI Podhaler
2014-001204-21Phase 4Terminated
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection, sponsored by Novartis. Primary endpoint: Change in lung clearance index (LCI). Started Aug 2014; status: terminated.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2014-001204-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001204-21.